Drug recall · September 25, 2019
Fexofenadine Hydrochloride Tablets USP recall
Why: Failed Impurities/Degradation Specifications
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Fexofenadine Hydrochloride Tablets USP, 180 mg, packaged in a) 30-count carton (NDC 70677-0008-2) and b) 15-count carton (NDC 70677-0008-1), sunmark, Distributed by McKesson, One Post Street, San Francisco, CA 94104.
- Lots / codes
Lot #s: a) 067180016B, Exp 05/21 and b) 067180024F1, Exp 07/21
- Quantity
- a) 11,928 cartons; b) 288 cartons
- Company
- Aurolife Pharma, LLC, Dayton, NJ
- Distribution
- Nationwide in the USA
- Initiated
- August 23, 2019 · Voluntary: Firm initiated
- Classified
- September 17, 2019
- Reported
- September 25, 2019
- Ended
- August 16, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Fexofenadine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.